Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2025-04-15 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于使用部分闲置募集资金委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of part of its idle raised funds for entrusted financial management (investment in low-risk financial products). It details the amount, purpose, risk analysis, approval procedures, and regulatory compliance related to the use of raised funds. The document references regulatory approvals, fundraising details, and investment plans but does not contain actual financial statements or comprehensive financial data. The document length is 3878 characters, which is relatively short and reads like a formal announcement rather than a full financial report. It is not an annual or interim report, audit report, or earnings release. It is not a call transcript or management report. It is a regulatory announcement about the use of raised funds and investment activities. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including the use of raised funds.
2025-04-15 Chinese
益丰药房第五届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifteenth meeting of the fifth board of directors of Yifeng Pharmacy Chain Co., Ltd. It details the meeting date, attendance, voting results, and specific proposals approved by the board, including the use of idle raised funds for temporary working capital and entrusted financial management. The document does not contain financial statements or detailed financial analysis but is a corporate governance announcement about board decisions. It is not an annual report, audit report, earnings release, or any financial report. It is also not a proxy solicitation or voting results announcement. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short (1324 characters), and it is a direct announcement of board resolutions, not a report publication announcement or regulatory filing. Therefore, the correct classification is MANG with high confidence.
2025-04-15 Chinese
益丰药房关于贯彻落实“提质增效重回报”专项行动暨控股股东提议实施2024年度现金分红的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from the company regarding a proposal by the controlling shareholder to implement a cash dividend for the fiscal year 2024. It discusses the dividend proposal, the shareholder meeting voting intentions, and the company's commitment to stable dividends. The document is short (930 characters) and does not contain actual financial statements or detailed financial data. It is an announcement about dividend distribution plans rather than the dividend notice itself or a full financial report. Therefore, it fits best as a Notice of Dividend Amount (DIV) announcement, as it informs shareholders about the proposed dividend amount and related details.
2025-04-08 Chinese
益丰药房关于可转债转股结果暨股份变动公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company about the results of convertible bond conversions and the resulting changes in share capital. It provides specific data on the amount of bonds converted into shares, the remaining unconverted bonds, and the changes in share capital as of March 31, 2025. The document is relatively short (1732 characters) and focuses on the conversion results and shareholding changes rather than providing a full financial report or detailed analysis. This type of document fits the category of 'Capital/Financing Update' (CAP), as it updates investors on financing activities related to convertible bonds and share capital changes. It is not an annual or interim report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2025-04-02 Chinese
益丰药房关于高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management person, specifically the vice president of the company. It includes statements about the resignation, its effective date, and the impact on the company. There is no financial data, no mention of a report or meeting, and it focuses solely on management changes. According to the filing definitions, this fits the category of 'Board/Management Information' (MANG). The document length is short and it is not a report publication or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2025-04-02 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司2022年限制性股票激励计划部分限制性股票回购注销实施的法律意见书
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the repurchase and cancellation of restricted shares under a 2022 restricted stock incentive plan by the company. It details the legal compliance, procedures, and approvals related to the stock repurchase and cancellation. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a share repurchase transaction. This fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length is 2831 characters, which is consistent with a detailed legal opinion rather than a brief announcement or a full report. Therefore, the classification is POS with high confidence.
2025-03-20 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.